These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 25406834)

  • 1. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
    Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
    BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
    Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
    J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
    Hasinoff BB; Patel D; Wu X
    Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
    Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
    Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
    Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
    Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.
    Yan T; Deng S; Metzger A; Gödtel-Armbrust U; Porter AC; Wojnowski L
    Mol Cancer Ther; 2009 May; 8(5):1075-85. PubMed ID: 19417146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
    Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
    Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
    Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
    Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.
    Bures J; Jirkovska A; Sestak V; Jansova H; Karabanovich G; Roh J; Sterba M; Simunek T; Kovarikova P
    Toxicology; 2017 Dec; 392():1-10. PubMed ID: 28941780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
    Lue Y; Gao C; Swerdloff R; Hoang J; Avetisyan R; Jia Y; Rao M; Ren S; Atienza V; Yu J; Zhang Y; Chen M; Song Y; Wang Y; Wang C
    Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H634-H643. PubMed ID: 29775411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
    Jirkovská A; Karabanovich G; Kubeš J; Skalická V; Melnikova I; Korábečný J; Kučera T; Jirkovský E; Nováková L; Bavlovič Piskáčková H; Škoda J; Štěrba M; Austin CA; Šimůnek T; Roh J
    J Med Chem; 2021 Apr; 64(7):3997-4019. PubMed ID: 33750129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
    Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
    PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
    Hasinoff BB; Patel D; Wu X
    Cardiovasc Toxicol; 2020 Jun; 20(3):312-320. PubMed ID: 31773441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.
    Thougaard AV; Langer SW; Hainau B; Grauslund M; Juhl BR; Jensen PB; Sehested M
    Toxicology; 2010 Feb; 269(1):67-72. PubMed ID: 20079798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
    Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
    Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
    Bavlovič Piskáčková H; Jansová H; Kubeš J; Karabanovich G; Váňová N; Kollárová-Brázdová P; Melnikova I; Jirkovská A; Lenčová-Popelová O; Chládek J; Roh J; Šimůnek T; Štěrba M; Štěrbová-Kovaříková P
    Sci Rep; 2021 Feb; 11(1):4456. PubMed ID: 33627707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.
    Shapiro AB; Austin CA
    Anal Biochem; 2014 Mar; 448():23-9. PubMed ID: 24309019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.